Psychosomatic Medicine Faster Service from Outside North America
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published online before print September 10, 2007
Psychosom Med 2007, doi:10.1097/PSY.0b013e318148c19a
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blumenthal, J. A.
Right arrow Articles by Sherwood, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blumenthal, J. A.
Right arrow Articles by Sherwood, A.
Related Collections
Right arrow Exercise
Right arrow Depression
Right arrow Therapeutic Interventions
© 2007 by American Psychosomatic Society

Original Article


Received March 16, 2007
Returned for revision May 14, 2007

Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder

James A. Blumenthal , PhD, Michael A. Babyak , PhD, P. Murali Doraiswamy , MD, Lana Watkins , PhD, Benson M. Hoffman , PhD, Krista A. Barbour , PhD, Steve Herman , PhD, W. Edward Craighead , PhD, Alisha L. Brosse , PhD, Robert Waugh , MD, Alan Hinderliter , MD, Andrew Sherwood , PhD



   Abstract

Objective: To assess whether patients receiving aerobic exercise training performed either at home or in a supervised group setting achieve reductions in depression comparable to standard antidepressant medication (sertraline) and greater reductions in depression compared to placebo controls. Methods: Between October 2000 and November 2005, we performed a prospective, randomized controlled trial (SMILE study) with allocation concealment and blinded outcome assessment in a tertiary care teaching hospital. A total of 202 adults (153 women; 49 men) diagnosed with major depression were assigned randomly to one of four conditions: supervised exercise in a group setting; home-based exercise; antidepressant medication (sertraline, 50–200 mg daily); or placebo pill for 16 weeks. Patients underwent the structured clinical interview for depression and completed the Hamilton Depression Rating Scale (HAM-D). Results: After 4 months of treatment, 41% of the participants achieved remission, defined as no longer meeting the criteria for major depressive disorder (MDD) and a HAM-D score of <8. Patients receiving active treatments tended to have higher remission rates than the placebo controls: supervised exercise = 45%; home-based exercise = 40%; medication = 47%; placebo = 31% (p = .057). All treatment groups had lower HAM-D scores after treatment; scores for the active treatment groups were not significantly different from the placebo group (p = .23). Conclusions: The efficacy of exercise in patients seems generally comparable with patients receiving antidepressant medication and both tend to be better than the placebo in patients with MDD. Placebo response rates were high, suggesting that a considerable portion of the therapeutic response is determined by patient expectations, ongoing symptom monitoring, attention, and other nonspecific factors.

Key Words: depression, exercise, antidepressant medication, selective serotonin reuptake inhibitors.




This article has been cited by other articles:


Home page
Psychosom. Med.Home page
U. F. Malt
EXERCISE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: STILL A LONG WAY TO GO
Psychosom Med, February 1, 2008; 70(2): 263 - 263.
[Full Text] [PDF]


Home page
Psychosom. Med.Home page
J. S. Ford
EXERCISE, PHARMACOTHERAPY, AND DEPRESSION
Psychosom Med, February 1, 2008; 70(2): 263 - 263.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Psychosomatic Society